Ikenna Okafor

Ikenna Okafor asked for a breakdown of sales for each ZORYVE SKU and the expected growth trends for different SKUs going into 2026.

Answer

Todd Edwards, Chief Commercial Officer, confirmed meaningful growth across all ZORYVE SKUs, with ZORYVE foam showing increased demand due to its two indications (seborrheic dermatitis and scalp/body psoriasis). He anticipates continued growth across the portfolio in 2026, highlighting the products' differentiation, once-daily dosing, and effectiveness for long-term disease control. Frank Watanabe, President and CEO, noted that RX split data provides a fairly accurate depiction of SKU split, as gross-to-nets are effectively the same across SKUs. Lata Vyravan, Chief Financial Officer, added that net sales are broken out by SKU in the reported financial statements.

Ikenna Okafor from TD Cowen asked why Arcutis did not break out sales for individual ZORYVE SKUs in their presentation and requested insights into expected growth trends for the different SKUs in 2026.

Answer

Chief Commercial Officer Todd Edwards stated that all SKUs experienced meaningful growth in Q4 2025, with ZORYVE foam showing increased demand due to its two indications. He anticipates continued growth across the portfolio in 2026, highlighting the products' differentiation. President and CEO Frank Watanabe suggested that RX split data provides a fairly accurate depiction of SKU sales, as gross-to-nets are similar across SKUs, with a slight lag for new launches. CFO Lata Vyravan noted that net sales are broken out by SKU in the reported financial statements.